Genentech Reports Two-Year Data of Evrysdi (risdiplam) for People with Type 2 or Type 3 SMA

 Genentech Reports Two-Year Data of Evrysdi (risdiplam) for People with Type 2 or Type 3 SMA

Genentech Reports Two-Year Data of Evrysdi (risdiplam) for People with Type 2 or Type 3 SMA

Shots:

  • Genentech reports the new 2yrs. data from part 2 of SUNFISH study assessing Evrysdi vs PBO in people aged 2-25 years with Type 2 or Type 3 SMA
  • Results: improvement in maintained motor function b/w 12-24mos. as measured by MFM-32; change from baseline in SMAIS score; stabilized motor function after 12mos. as per MFM-32, RULM and HFMSE; increased motor function as measured by RULM and HFMSE b/w 12-24mos.
  • Evrysdi is the first and only at home SMA treatment which has proven efficacy across adults, children and infants 2 months and older

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Fortune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post